Literature DB >> 25197078

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.

Haitao Hu1, Michael A Eller2, Shah Zafar2, Yu Zhou3, Mengnan Gu4, Zhi Wei4, Jeffrey R Currier5, Mary A Marovich6, Hannah N Kibuuka7, Robert T Bailer8, Richard A Koup8, Merlin L Robb2, Nelson L Michael9, Jerome H Kim9, Silvia Ratto-Kim2.   

Abstract

Efficacy trials of adenovirus 5-vectored candidate HIV vaccines [recombinant Ad5 (rAd5)-HIV] were halted for futility due to lack of vaccine efficacy and unexpected excess HIV infections in the vaccine recipients. The potential immunologic basis for these observations is unclear. We comparatively evaluated the HIV susceptibility and phenotypes of human CD4 T cells specific to Ad5 and CMV, two viruses that have been used as HIV vaccine vectors. We show that Ad5-specific CD4 T cells, either induced by natural Ad5 exposure or expanded by rAd5 vaccination, are highly susceptible to HIV in vitro and are preferentially lost in HIV-infected individuals compared with CMV-specific CD4 T cells. Further investigation demonstrated that Ad5-specific CD4 T cells selectively display a proinflammatory Th17-like phenotype and express macrophage inflammatory protein 3α and α4β7 integrin, suggestive of gut mucosa homing potential of these cells. Analysis of HIV p24 and cytokine coexpression using flow cytometry revealed preferential infection of IL-17- and IL-2-producing, Ad5-specific CD4 T cells by HIV in vitro. Our data suggest a potential mechanism explaining the excess HIV infections in vaccine recipients after rAd5-HIV vaccination and highlight the importance of testing the HIV susceptibility of vaccine-generated, vector and insert-specific CD4 T cells in future HIV vaccine studies.

Entities:  

Keywords:  AIDS; antigen-specific CD4 T cells; viral vectors

Mesh:

Substances:

Year:  2014        PMID: 25197078      PMCID: PMC4169982          DOI: 10.1073/pnas.1400446111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans.

Authors:  Michael A Eller; Leigh Anne Eller; Marc S Opollo; Benson J Ouma; Peter O Oballah; Lynee Galley; Chitraporn Karnasuta; Silvia Ratto Kim; Merlin L Robb; Nelson L Michael; Hannah Kibuuka; Fred Wabwire-Mangen; Barney S Graham; Deborah L Birx; Mark S de Souza; Josephine H Cox
Journal:  Vaccine       Date:  2007-09-17       Impact factor: 3.641

2.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

3.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

4.  Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.

Authors:  Gurvinder Kaur; Michael Tuen; Diana Virland; Sandra Cohen; Narinder K Mehra; Christian Münz; Sayed Abdelwahab; Alfredo Garzino-Demo; Catarina E Hioe
Journal:  Virology       Date:  2007-09-04       Impact factor: 3.616

5.  Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.

Authors:  Jason M Brenchley; Mirko Paiardini; Kenneth S Knox; Ava I Asher; Barbara Cervasi; Tedi E Asher; Phillip Scheinberg; David A Price; Chadi A Hage; Lisa M Kholi; Alexander Khoruts; Ian Frank; James Else; Timothy Schacker; Guido Silvestri; Daniel C Douek
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

6.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

7.  Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.

Authors:  Robert Paris; Robert A Kuschner; Leonard Binn; Stephen J Thomas; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Robert T Bailer; Nancy Sullivan; Richard A Koup
Journal:  Clin Vaccine Immunol       Date:  2014-03-12

8.  HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells.

Authors:  James Arthos; Claudia Cicala; Elena Martinelli; Katilyn Macleod; Donald Van Ryk; Danlan Wei; Zhen Xiao; Timothy D Veenstra; Thomas P Conrad; Richard A Lempicki; Sherry McLaughlin; Massimiliano Pascuccio; Ravindra Gopaul; Jonathan McNally; Catherine C Cruz; Nina Censoplano; Eva Chung; Kristin N Reitano; Shyam Kottilil; Diana J Goode; Anthony S Fauci
Journal:  Nat Immunol       Date:  2008-02-10       Impact factor: 25.606

9.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

10.  Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.

Authors:  Yongjun Guan; Sayed Abdelwahab; Roberta Kamin-Lewis; Anthony L DeVico; George K Lewis
Journal:  PLoS One       Date:  2008-10-22       Impact factor: 3.240

View more
  26 in total

1.  Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.

Authors:  Catia T Perciani; Bashir Farah; Rupert Kaul; Mario A Ostrowski; Salaheddin M Mahmud; Omu Anzala; Walter Jaoko; Kelly S MacDonald
Journal:  J Clin Invest       Date:  2019-01-22       Impact factor: 14.808

2.  Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Authors:  Holly E Janes; Kristen W Cohen; Nicole Frahm; Stephen C De Rosa; Brittany Sanchez; John Hural; Craig A Magaret; Shelly Karuna; Carter Bentley; Raphael Gottardo; Greg Finak; Douglas Grove; Mingchao Shen; Barney S Graham; Richard A Koup; Mark J Mulligan; Beryl Koblin; Susan P Buchbinder; Michael C Keefer; Elizabeth Adams; Chuka Anude; Lawrence Corey; Magdalena Sobieszczyk; Scott M Hammer; Peter B Gilbert; M Juliana McElrath
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

3.  Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models.

Authors:  Jennifer A Juno; Kathleen M Wragg; Anne B Kristensen; Wen Shi Lee; Kevin J Selva; Renee M van der Sluis; Anthony D Kelleher; Benjamin R Bavinton; Andrew E Grulich; Sharon R Lewin; Stephen J Kent; Matthew S Parsons
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

Review 4.  Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.

Authors:  James L Riley; Luis J Montaner
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

5.  Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.

Authors:  Nicolas Çuburu; Kening Wang; Kyle N Goodman; Yuk Ying Pang; Cynthia D Thompson; Douglas R Lowy; Jeffrey I Cohen; John T Schiller
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

6.  Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580.

Authors:  Edrous Alamer; Chaojie Zhong; Zhiqing Liu; Qingli Niu; Fuquan Long; Lulu Guo; Benjamin B Gelman; Lynn Soong; Jia Zhou; Haitao Hu
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

Review 7.  HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

Authors:  Haitao Hu; Fengliang Liu; Jerome Kim; Silvia Ratto-Kim
Journal:  Expert Rev Vaccines       Date:  2016-02-17       Impact factor: 5.217

8.  Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine.

Authors:  Nanxi Wang; Zhe Yuan; Wei Niu; Qingsheng Li; Jiantao Guo
Journal:  J Chem Technol Biotechnol       Date:  2017-02-02       Impact factor: 3.174

Review 9.  CD4+ T Cell Subsets and Pathways to HIV Latency.

Authors:  Luis M Agosto; Andrew J Henderson
Journal:  AIDS Res Hum Retroviruses       Date:  2018-07-09       Impact factor: 2.205

10.  Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.

Authors:  Fengliang Liu; Xiuzhen Fan; Sarah Auclair; Monique Ferguson; Jiaren Sun; Lynn Soong; Wei Hou; Robert R Redfield; Deborah L Birx; Silvia Ratto-Kim; Merlin L Robb; Jerome H Kim; Nelson L Michael; Haitao Hu
Journal:  PLoS Pathog       Date:  2016-06-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.